Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.41 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277668 | 0.84 | ALDH1A1 (0.50) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 | |
| SCHEMBL16181352 | 0.83 | L3MBTL1 (0.47) | ALDH1A1OPRM1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL15998851 | 0.82 | ALDH1A1 (0.47) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 | |
| SCHEMBL13360768 | 0.82 | ALDH1A1 (0.52) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 | |
| SCHEMBL16887629 | 0.81 | OPRM1 (0.42) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 | |
| SCHEMBL10074073 | 0.80 | ALDH1A1 (0.45) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 | |
| SCHEMBL180620 | 0.80 | — | — | |
| SCHEMBL20756575 | 0.80 | BLM (0.57) | ALDH1A1BLMCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2739418 | 0.80 | BLM (0.57) | ALDH1A1BLMCHRNB2CHRNA3CHRNA4 | |
| SCHEMBL13804168 | 0.78 | ALDH1A1 (0.48) | ALDH1A1OPRM1BLMCHRNB2CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023186-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2021-01-28 | — | — | US | disclosed |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2017-07-13 | — | — | US | disclosed |
| US-9636412-B2 | Conjugates of an anti-TNF-alpha antibody | NEKTAR THERAPEUTICS (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2017-02-09 | — | — | US | disclosed |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS | 2016-06-23 | — | — | US | disclosed |
| US-9347054-B2 | Polymer factor IX moiety conjugates | NEKTAR THERAPEUTICS (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS | 2016-02-04 | — | — | US | disclosed |
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | NEKTAR THERAPEUTICS | 2015-02-05 | — | — | US | disclosed |
| US-8889831-B2 | Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate | NEKTAR THERAPEUTICS (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | NEKTAR THERAPEUTICS | 2014-11-06 | — | — | US | disclosed |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-05-13 | — | — | US | disclosed |
| US-7714114-B2 | Conjugates of an EPO moiety and a polymer | NEKTAR THERAPEUTICS (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | NEKTAR THERAPEUTICS (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090280550-A1 | Polymer-Factor IX Moiety Conjugates | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS | 2008-03-06 | — | — | US | disclosed |
| US-7199223-B2 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038422-A1 | UNIT DOSAGE FORMS OF PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYMER-FACTOR VIII POLYPEPTIDE CONJUGATE | F8, F13B, F13A1 | ALDH1A1 3099/4885OPRM1 1815/4885BLM 523/4885 |
| US-20090041714-A1 | Binding element comprising polyethylene glycol and antihemophilic factor for use in treatment of hemophilia | F13B, F8, F13A1 | ALDH1A1 3597/4885OPRM1 2458/4885BLM 2637/4885 |
| US-20140328791-A1 | Conjugates of an IL-2 Moiety and a Polymer | IL2, IL2RA, ILF2 | ALDH1A1 2509/4885OPRM1 2993/4885BLM 2970/4885 |
| US-20100120689-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885OPRM1 3681/4885BLM 538/4885 |
| US-20170035896-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885OPRM1 3101/4885BLM 1229/4885 |
| US-20100120982-A1 | POLYMER-FACTOR IX MOIETY CONJUGATES | F9, F13A1, F13B | ALDH1A1 2876/4885OPRM1 3142/4885BLM 1267/4885 |
| US-20100021481-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2494/4885OPRM1 1886/4885BLM 3468/4885 |
| US-20100125049-A1 | POLYMER FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2770/4885OPRM1 3681/4885BLM 538/4885 |
| US-20170196975-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2449/4885OPRM1 1855/4885BLM 3656/4885 |
| US-20100130684-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885OPRM1 3101/4885BLM 1229/4885 |
| US-20160030587-A1 | CONJUGATES OF AN ANTI-TNF-ALPHA ANTIBODY | TNF, TNFRSF1A, TNFRSF9 | ALDH1A1 2494/4885OPRM1 1886/4885BLM 3468/4885 |
| US-20160175402-A1 | POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | ALDH1A1 2572/4885OPRM1 3711/4885BLM 489/4885 |
| US-20080058504-A1 | Water soluble polyoxyethylene glylcol polyvinylpyrrolidone, polyvinyl alcohol, polyoxazoline, and/or polyacryloylmorpholine, conjugated to antihemophilic factor | F8, F13A1, F13B | ALDH1A1 2393/4885OPRM1 194/4885BLM 1443/4885 |
| US-20210023186-A1 | POLYMER FACTOR IX MOIETY CONJUGATES | F9, F13A1, F8 | ALDH1A1 3118/4885OPRM1 3101/4885BLM 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.